We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.75 | 4.24% | 43.01 | 41.91 | 44.34 | 43.60 | 41.05 | 41.29 | 1,066,646 | 00:55:10 |
From May 2019 to May 2024
By Chelsey Dulaney
Isis Pharmaceuticals Inc. (ISIS) has agreed to license its experimental anticlotting drug to a Bayer AG (BAYRY, BAYN.XE) unit for an initial payment of $100 million.
Bayer HealthCare will develop and commercialize the drug. Bayer plans to evaluate the drug, ISIS-FXI, in patients who can't use anticoagulants, such as patients with a high risk of bleeding.
Bayer said the drug complements its pipeline of thrombosis treatments. Thrombosis is a process involving blood-clot formation that can result in heart attacks and strokes.
Isis Pharmaceuticals is also eligible for a $55 million payment after a phase-two study in patients with compromised kidney function. The company will also be eligible for milestone payments and royalties.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
